JAK inhibitor 'highly effective' for alopecia areata

Trial participants taking the oral biologic had significantly improved hair regrowth and adverse events were largely mild

The rheumatoid arthritis drug baricitinib could be a highly effective therapeutic option for patients with severe alopecia areata, according to results from two phase III trials.

International researchers — including several leading Australian dermatologists — say the Janus kinase (JAK) inhibitor resulted in significantly higher rates of hair regrowth compared with placebo.

Although the drug was associated with a higher rate of adverse events, clinicians say findings from

Latest